AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Despite WHI, HERS II studies, HRT market will experience robust growth.
2003 MAY 8 - (NewsRx.com & NewsRx.net) -- Decision Resources, Inc., finds that despite negative impact of the Women's Health Initiative (WHI) and the Heart and Estrogen/Progestin Replacement Study (HERS II), the hormone replacement therapy (HRT) drug market will experience robust growth.
According to the new Pharmacor study entitled Hormone Replacement Therapy, one such drug that will take advantage of patients' and physicians' concerns with traditional HRT products is Eli Lilly's Evista. Evista is currently the only selective estrogen receptor modulator (SERM) approved for the prevention and treatment of postmenopausal osteoporosis.
"Although some women who discontinued HRT immediately following the WHI and HERS II announcements have since resumed their HRT regimens, many thought leaders believe that these two studies irreparably damaged physician and patient confidence in the safety of HRT agents. As a result, it is unlikely the percentage of drug-treated women will reach the levels seen before the ...
- Marketed and Emerging Biologic Agents Will Be the Greatest Drivers of Sales...
- Press release article from: PR Newswire April 4, 2005 700+ words
...PRNewswire/ -- Decision Resources, Inc., one of...biologic agents in the United States, where use and sales...Monie, analyst at Decision Resources. "However, Medicare...inhibitors in the United States." Rheumatoid Arthritis...
- Yentreve/Ariclaim Will Dominate European Market for Treatment of Stress Urinary...
- Press release article from: PR Newswire March 8, 2005 700+ words
...uncertain future in the United States could greatly restrict...urinary incontinence in the United States after the FDA reported...Kat Lynch, analyst at Decision Resources. "Without a presence in the United States -- the largest regional...
- Generic Erosion to Significantly Stunt the Growth of the Bipolar Disorder Drug...
- Press release article from: PR Newswire August 31, 2004 700+ words
...PRNewswire/ -- Decision Resources, Inc., one...market in the United States. According...65% in the United States by 2013; from...analyst at Decision Resources. "Generics...especially in the United States. Sales after...
- Merck's Vioxx Will Chase But Never Catch Pfizer's Celebrex; Pfizer's COX-2...
- Press release article from: PR Newswire September 16, 2002 700+ words
...Bain, Ph.D., analyst at Decision Resources. "Although Arcoxia/Vioxx...pharmaceutical markets (the United States, France, Germany, Italy...States. About Pharmacor from Decision Resources Pharmacor is a unique family...
- Eli Lilly's Ruboxistaurin, The First Disease-Modifying Agent for Use In Distal...
- Press release article from: PR Newswire December 16, 2002 700+ words
...DSP) market in the United States and Europe," said...D., analyst at Decision Resources. "The drug's...the major markets (United States, France, Germany...About Pharmacor from Decision Resources Pharmacor is a unique...
- Follow-on TNF-Alpha Inhibitors Will Become the First $1 Billion Biogeneric...
- Press release article from: PR Newswire October 24, 2007 700+ words
...PRNewswire/ -- Decision Resources, Inc...across the United States and Europe...produced by Decision Resources. It includes...specialists from the United States, France...biogenerics. About Decision Resources Decision Resources...
- Formulary Decision Making in the United States.
- Press release article from: M2 Presswire April 29, 2009 700+ words
...Decision Making in the United States(C)1994-2009...announced the addition of Decision Resources, Inc.'s new report...Decision Making in the United States" to their offering...decision making in the United States. Who are the key...
- Drug Benefit Trends in the United States - Assessing the Outlook and...
- Press release article from: M2 Presswire April 9, 2009 700+ words
...Benefit Trends in the United States - Assessing the Outlook...announced the addition of Decision Resources, Inc.'s new report...Benefit Trends in the United States" to their offering...pharmaceutical markets, the United States relies on the private...
- Research and Markets: Formulary Decision Making in the United States.
- Press release article from: Business Wire April 29, 2009 700+ words
...announced the addition of Decision Resources, Inc.'s new report...Formulary Decision Making in the United States" to their offering. The...formulary decision making in the United States. Who are the key players...reimbursement environment in the United States is ...
- Research and Markets: Drug Benefit Trends in the United States - Assessing the...
- Press release article from: Business Wire April 9, 2009 700+ words
...the addition of Decision Resources, Inc.'s new...Benefit Trends in the United States" to their offering...pharmaceutical markets, the United States relies on the private...benefits in the United States? How many U.S...
Source: HighBeam Research, Despite WHI, HERS II studies, HRT market will experience robust...